Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Arch Virol
2 Cell
4 Epidemiol Infect
2 J Immunol
10 J Infect
8 J Infect Dis
1 J Neurosurg Pediatr
1 J Virol
1 Lancet
1 MMWR Morb Mortal Wkly Rep
1 PLoS Biol
1 PLoS Med
23 PLoS One
4 Proc Natl Acad Sci U S A
21 Vaccine
1 Virology
8 Virus Res

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Arch Virol

  1. ZHOU Y, Chen Z
    Mpox: a review of laboratory detection techniques.
    Arch Virol. 2023;168:221.
    PubMed         Abstract available


  2. LOOI MK
    Covid-19: Hospital admissions rise in England amid fears of new variant and waning immunity.
    BMJ. 2023;382:p1833.

    Covid-19: Payment to general practices to deliver vaccines to be cut by 25.
    BMJ. 2023;382:1821.

    Covid-19: Latin America defies nationalism and circumstance to develop its own vaccines.
    BMJ. 2023;382:1351.

    Covid-19: US agency launches raft of clinical trials of treatments for long covid.
    BMJ. 2023;382:p1797.


    Unveiling TMEM106B: SARS-CoV-2's secret entrance to the cell.
    Cell. 2023;186:3329-3331.
    PubMed         Abstract available

  7. BAGGEN J, Jacquemyn M, Persoons L, Vanstreels E, et al
    TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.
    Cell. 2023;186:3427-3442.
    PubMed         Abstract available

    Epidemiol Infect

  8. DE CARVALHO FS, Slack SD, Barbosa-Junior F, de Campos MR, et al
    Genomic epidemiology of SARS-CoV-2 in large university hospital cohort: the UnCoVER-Brazil project.
    Epidemiol Infect. 2023;151:e126.
    PubMed         Abstract available

  9. GERRITZEN I, Brus IM, Spronk I, Biere-Rafi S, et al
    Identification of post-COVID-19 condition phenotypes, and differences in health-related quality of life and healthcare use: a cluster analysis.
    Epidemiol Infect. 2023;151:e123.
    PubMed         Abstract available

  10. ROGERS JH, Cox SN, Link AC, Nwanne G, et al
    Incidence of SARS-CoV-2 infection and associated risk factors among staff and residents at homeless shelters in King County, Washington: an active surveillance study.
    Epidemiol Infect. 2023;151:e129.
    PubMed         Abstract available

  11. LUO E, Zhong Q, Wen Y, Cai J, et al
    Development and external validation of a prognostic tool for nonsevere COVID-19 inpatients.
    Epidemiol Infect. 2023;151:e128.
    PubMed         Abstract available

    J Immunol

  12. CAO L, Hui X, Xu T, Mao H, et al
    The RNA-Splicing Ligase RTCB Promotes Influenza A Virus Replication by Suppressing Innate Immunity via Interaction with RNA Helicase DDX1.
    J Immunol. 2023 Aug 9:ji2200799. doi: 10.4049/jimmunol.2200799.
    PubMed         Abstract available

  13. SANDBERG JK, Leeansyah E, Eller MA, Shacklett BL, et al
    The Emerging Role of MAIT Cell Responses in Viral Infections.
    J Immunol. 2023;211:511-517.
    PubMed         Abstract available

    J Infect

  14. VARASI I, Lai A, Fiaschi L, Bergna A, et al
    Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination.
    J Infect. 2023 Jun 30:S0163-4453(23)00342-0. doi: 10.1016/j.jinf.2023.

  15. DOWELL AC, Waiblinger D, Wright J, Ladhani SN, et al
    Nucleocapsid-Specific Antibodies as a Correlate of Protection against SARS-CoV-2 Reinfection in Children.
    J Infect. 2023 Jun 28:S0163-4453(23)00340-7. doi: 10.1016/j.jinf.2023.

  16. SU HC, Lai ZL, Chang YC, Cheng MY, et al
    Genomic characteristics of SARS-CoV-2 variants and their clinical impact on patients with COVID-19 in Taiwan.
    J Infect. 2023 Jun 27:S0163-4453(23)00341-9. doi: 10.1016/j.jinf.2023.

  17. KELLY E, Greenland M, de Whalley PCS, Aley PK, et al
    Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial.
    J Infect. 2023 Jun 16:S0163-4453(23)00330-4. doi: 10.1016/j.jinf.2023.
    PubMed         Abstract available

  18. STANKUNAS M, Dziugys A, Skarbalius G, Misiulis E, et al
    J Infect. 2023 Jun 15:S0163-4453(23)00333-X. doi: 10.1016/j.jinf.2023.

  19. TAUCHER C, Lazarus R, Dellago H, Maurer G, et al
    Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COM
    J Infect. 2023 Jul 3:S0163-4453(23)00367-5. doi: 10.1016/j.jinf.2023.
    PubMed         Abstract available

  20. BAYHAN GI, Guner R, Yahsi A, Ozkul A, et al
    Evaluation of the neutralizing antibody response against the omicron variant produced by heterologous or hybrid immunity: How does the fifth dose of COVID-19 vaccine affect the neutralizing antibody response?
    J Infect. 2023 Jul 4:S0163-4453(23)00369-9. doi: 10.1016/j.jinf.2023.

  21. RISSMANN M, Veldhuis Kroeze EJB, Tielens AGM, Rockx B, et al
    Influence of a chronic Schistosoma mansoni infection on the outcomes of a SARS-CoV-2 infection in the hamster model.
    J Infect. 2023 Jul 5:S0163-4453(23)00374-2. doi: 10.1016/j.jinf.2023.

  22. FEELISCH M, Clark AD, Cumpstey AF, Santolini J, et al
    Long COVID: Potential role of the Reactive Species Interactome.
    J Infect. 2023 Jul 11:S0163-4453(23)00376-6. doi: 10.1016/j.jinf.2023.

  23. KAMBOJ M, Laracy JC, Usiak S, Babady NE, et al
    Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.
    J Infect. 2023 Jul 13:S0163-4453(23)00378-X. doi: 10.1016/j.jinf.2023.

    J Infect Dis

  24. ROUPHAEL N, Bausch-Jurken M
    COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

    Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

    Foreword: Preventing COVID-19 Among the Immunocompromised Population.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

  27. PARIS R
    SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

  28. BONANNI P, Ceddia F, Dawson R
    A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

  29. ANTINORI A, Bausch-Jurken M
    The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

  30. HALL VG, Teh BW
    COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

  31. FINCKH A, Ciurea A, Raptis CE, Rubbert-Roth A, et al
    Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

    J Neurosurg Pediatr

  32. ANGELO SJ, Anderson MG, Sutter PA, Halloran PJ, et al
    Changes in the epidemiology of pediatric sinogenic and otogenic intracranial infections during the COVID-19 pandemic: a single-institution study.
    J Neurosurg Pediatr. 2023;32:231-241.
    PubMed         Abstract available

    J Virol

  33. THOMPSON D, Cismaru CV, Rougier JS, Schwemmle M, et al
    The M2 proteins of bat influenza A viruses reveal atypical features compared to conventional M2 proteins.
    J Virol. 2023 Aug 4:e0038823. doi: 10.1128/jvi.00388.
    PubMed         Abstract available


  34. GLEASON JL, Tamburro R, Signore C
    Promoting Data Harmonization of COVID-19 Research in Pregnant and Pediatric Populations.
    JAMA. 2023 Jul 20. doi: 10.1001/jama.2023.10835.

  35. MCGARRY BE, Sommers BD, Wilcock AD, Grabowski DC, et al
    Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes.
    JAMA. 2023 Jul 14:e2312945. doi: 10.1001/jama.2023.12945.


  36. Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response.
    Lancet. 2023 May 26:S0140-6736(23)00964-9. doi: 10.1016/S0140-6736(23)00964.

    MMWR Morb Mortal Wkly Rep

  37. ROMANSON B, Moro PL, Su JR, Marquez P, et al
    Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged >/=12 Years - United States, July 13, 2022-March 13, 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:850-851.

    PLoS Biol

  38. LOBINSKA G, Pilpel Y, Nowak MA
    Evolutionary safety of lethal mutagenesis driven by antiviral treatment.
    PLoS Biol. 2023;21:e3002214.
    PubMed         Abstract available

    PLoS Med

  39. XIONG X, Lui DTW, Chung MSH, Au ICH, et al
    Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
    PLoS Med. 2023;20:e1004274.
    PubMed         Abstract available

    PLoS One

  40. UMAR Z, Choi SY, Teplova T, Sokolova T, et al
    Dynamic spillovers and portfolio implication between green cryptocurrencies and fossil fuels.
    PLoS One. 2023;18:e0288377.
    PubMed         Abstract available

  41. SUGIMOTO A, Numaguchi T, Chihama R, Takenaka Y, et al
    Identification of novel lactic acid bacteria with enhanced protective effects against influenza virus.
    PLoS One. 2023;18:e0273604.
    PubMed         Abstract available

  42. WEISS CM, Liu H, Ball EE, Hoover AR, et al
    N-dihydrogalactochitosan reduces mortality in a lethal mouse model of SARS-CoV-2.
    PLoS One. 2023;18:e0289139.
    PubMed         Abstract available

  43. AL-SIBANI N, Chan MF, Al-Huseini S, Al Kharusi N, et al
    Exploring Hikikomori-like idiom of distress a year into the SARS-CoV-2 pandemic in Oman: Factorial validity of the 25-item Hikikomori Questionnaire, prevalence and associated factors.
    PLoS One. 2023;18:e0279612.
    PubMed         Abstract available

  44. ABOELNAGA S, Czech K, Wielechowski M, Kotyza P, et al
    COVID-19 resilience index in European Union countries based on their risk and readiness scale.
    PLoS One. 2023;18:e0289615.
    PubMed         Abstract available

  45. FU L, Shi Y, Yang X, Zhang W, et al
    Enterprise resilience to the COVID-19 pandemic: The role of business environment.
    PLoS One. 2023;18:e0288722.
    PubMed         Abstract available

  46. SHRESTHA MR, Basnet A, Tamang B, Khadka S, et al
    Analysis of altered level of blood-based biomarkers in prognosis of COVID-19 patients.
    PLoS One. 2023;18:e0287117.
    PubMed         Abstract available

  47. WEST BT, Zhang S, Wagner J, Gatward R, et al
    Methods for improving participation rates in national self-administered web/mail surveys: Evidence from the United States.
    PLoS One. 2023;18:e0289695.
    PubMed         Abstract available

  48. ALHUDIRI I, Abusrewil Z, Dakhil O, Zwaik MA, et al
    Impact of vaccination and risk factors on COVID-19 mortality amid delta wave in Libya: A single center cohort study.
    PLoS One. 2023;18:e0289490.
    PubMed         Abstract available

  49. WACHIRA E, Chavan B, Nganga-Good C, Kingori C, et al
    The association between COVID-19 preventive behaviors and mental health conditions.
    PLoS One. 2023;18:e0289533.
    PubMed         Abstract available

  50. ABDELRAHIM R, Gao Z, Smith MJ, Newhook LA, et al
    The prevalence of pediatric asthma hospitalizations at different stages of the COVID-19 pandemic: A systematic review and meta-analysis study protocol.
    PLoS One. 2023;18:e0289538.
    PubMed         Abstract available

  51. OWENS CD, Bonin Pinto C, Mukli P, Szarvas Z, et al
    Vascular mechanisms leading to progression of mild cognitive impairment to dementia after COVID-19: Protocol and methodology of a prospective longitudinal observational study.
    PLoS One. 2023;18:e0289508.
    PubMed         Abstract available

  52. TORAIF N, Gondal N, Paudel P, Frisellaa A, et al
    From colorblind to systemic racism: Emergence of a rhetorical shift in higher education discourse in response to the murder of George Floyd.
    PLoS One. 2023;18:e0289545.
    PubMed         Abstract available

  53. DINH A, Drouet F, Dechartres A, Yordanov Y, et al
    Pregnant women with mild COVID-19 followed in community setting by telemedicine, and factors associated with unfavorable outcome.
    PLoS One. 2023;18:e0288845.
    PubMed         Abstract available

  54. KAO SZ, Tutwiler MS, Ekwueme DU, Truman BI, et al
    Better data for decision-making through Bayesian imputation of suppressed provisional COVID-19 death counts.
    PLoS One. 2023;18:e0288961.
    PubMed         Abstract available

  55. HERNANDEZ BAUTISTA PF, Grajales Muniz C, Cabrera Gaytan DA, Rojas Mendoza T, et al
    Impact of vaccination on infection or death from COVID-19 in individuals with laboratory-confirmed cases: Case-control study.
    PLoS One. 2023;18:e0265698.
    PubMed         Abstract available

  56. TAM CC, Qiao S, Garrett C, Zhang R, et al
    Substance use, psychiatric symptoms, personal mastery, and social support among COVID-19 long haulers: A compensatory model.
    PLoS One. 2023;18:e0289413.
    PubMed         Abstract available

  57. ENDRIYAS M, Shibru E, Hussen M, Melka M, et al
    Knowledge, attitudes and practices towards COVID-19: Community survey in southern Ethiopia.
    PLoS One. 2023;18:e0288430.
    PubMed         Abstract available

  58. FLOOD MT, Sharp J, Bruggink J, Cormier M, et al
    Understanding the efficacy of wastewater surveillance for SARS-CoV-2 in two diverse communities.
    PLoS One. 2023;18:e0289343.
    PubMed         Abstract available

  59. ALLEN LP, Ellis L, Engleton C, Valerio VL, et al
    Plant medicine usage of people living with type 2 diabetes mellitus in Belize: A qualitative exploratory study.
    PLoS One. 2023;18:e0289212.
    PubMed         Abstract available

  60. FISTERA D, Kikull K, Risse J, Herrmann A, et al
    Point-of-care PCR testing of SARS-CoV-2 in the emergency department: Influence on workflow and efficiency.
    PLoS One. 2023;18:e0288906.
    PubMed         Abstract available

  61. KEGLER MC, Dekanosidze A, Torosyan A, Grigoryan L, et al
    Community coalitions for smoke-free environments in Armenia and Georgia: A mixed methods analysis of coalition formation, implementation and perceived effectiveness.
    PLoS One. 2023;18:e0289149.
    PubMed         Abstract available

  62. WEI SY, Lin LW
    Impacts of environmental uncertainty on investment stocks perception under the holiday effect.
    PLoS One. 2023;18:e0284745.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  63. MAIO N, Raza MK, Li Y, Zhang DL, et al
    An iron-sulfur cluster in the zinc-binding domain of the SARS-CoV-2 helicase modulates its RNA-binding and -unwinding activities.
    Proc Natl Acad Sci U S A. 2023;120:e2303860120.
    PubMed         Abstract available

  64. ZELLER MA, Ma J, Wong FY, Tum S, et al
    The genomic landscape of swine influenza A viruses in Southeast Asia.
    Proc Natl Acad Sci U S A. 2023;120:e2301926120.
    PubMed         Abstract available

  65. YANG L, Wang Z, Wang L, Vrancken B, et al
    Association of vaccination, international travel, public health and social measures with lineage dynamics of SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2023;120:e2305403120.
    PubMed         Abstract available

  66. TSANG TK, Wang C, Fang VJ, Perera RAPM, et al
    Reconstructing household transmission dynamics to estimate the infectiousness of asymptomatic influenza virus infections.
    Proc Natl Acad Sci U S A. 2023;120:e2304750120.
    PubMed         Abstract available


  67. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

    COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  69. WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
    Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
    Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  70. LU X, Masuda S, Horlad H, Katoh T, et al
    Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  71. CLOUSTON SAP, Hanes DW, Link BG
    Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
    Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  72. MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
    Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  73. TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
    Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  74. SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
    Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
    Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  75. SARNA M, Gebremedhin A, Richmond P, Levy A, et al
    Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia.
    Vaccine. 2023;41:5216-5220.
    PubMed         Abstract available

  76. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  77. SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
    Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
    Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  78. MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  79. CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
    Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
    Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  80. TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
    Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
    Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  81. LIU Y, Zhang A, Wang Y, Yang J, et al
    Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
    Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  82. AGRAWAL P, Damania D, Cseh A, Grab J, et al
    Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  83. MINCHIN J, Harris GH, Baumann S, Smith ER, et al
    Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
    Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  84. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
    Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  85. KIM S, Ko M, Heo Y, Lee YK, et al
    Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  86. MAC S, Shi S, Millson B, Tehrani A, et al
    Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
    Vaccine. 2023;41:5141-5149.
    PubMed         Abstract available

  87. HU S, Xiong C, Zhao Y, Yuan X, et al
    Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available


  88. UPRETY T, Sreenivasan CC, Thomas M, Hause B, et al
    Prevalence and characterization of seven-segmented influenza viruses in bovine respiratory disease complex.
    Virology. 2023;587:109859.
    PubMed         Abstract available

    Virus Res

  89. STRAKOVA P, Bednar P, Kotoucek J, Holoubek J, et al
    Antiviral activity of singlet oxygen-photogenerating perylene compounds against SARS-CoV-2: Interaction with the viral envelope and photodynamic virion inactivation.
    Virus Res. 2023;334:199158.
    PubMed         Abstract available

  90. BERNAL KDE, Whitehurst CB
    Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients.
    Virus Res. 2023;334:199157.
    PubMed         Abstract available

  91. WANG Z, Pan Q, Ma L, Zhao J, et al
    Anthracyclines inhibit SARS-CoV-2 infection.
    Virus Res. 2023;334:199164.
    PubMed         Abstract available

  92. ANDRADE-MOLINA DA, Morey-Leon GA, Munoz-Mawyin KE, Cruz-Fatuly FF, et al
    First sequenced cases of Omicron BA.2 sublineage in Ecuador.
    Virus Res. 2023;334:199169.
    PubMed         Abstract available

  93. STINCARELLI MA, Quagliata M, Di Santo A, Pacini L, et al
    SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein.
    Virus Res. 2023;334:199170.
    PubMed         Abstract available

  94. TAKAZAWA S, Kotaki T, Nakamura S, Utsubo C, et al
    Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities.
    Virus Res. 2023;334:199176.
    PubMed         Abstract available

  95. PRINS MLM, Prins C, de Vries JJC, Visser LG, et al
    Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers.
    Virus Res. 2023 Jul 18:199175. doi: 10.1016/j.virusres.2023.199175.
    PubMed         Abstract available

  96. TAI W, Zheng J, Zhang X, Shi J, et al
    MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection.
    Virus Res. 2023;334:199156.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.